Intellia Therapeutics, Inc. (NTLA) Thursday announced a strategic collaboration with ReCode Therapeutics to develop gene editing therapies for Cystic fibrosis. The financial aspect of the tie-up is not revealed.
The collaboration is expected to leverage Intellia's proprietary CRISPR-based gene editing platform, including its DNA writing technology, and ReCode's proprietary Selective Organ Targeting lipid nanoparticle delivery platform to correct one or more CF disease-causing gene mutations.
As per the agreement, Intellia will be responsible for the design of the editing strategy, while ReCode will lead the subsequent preclinical, clinical development as well as worldwide commercialization.
Cystic fibrosis is a genetic disease caused by mutations in the CFTR gene, leading to the accumulation of thick mucus in the lungs, digestive systems, and other organs. It can result in life-threatening infections, respiratory failure, and other serious complications.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.